Doctor showing tablet to patient. Management of metastatic renal cell carcinoma should be highly individualized, according to investigators. Preoperative systemic therapy does not lead to worse ...

AUSTIN, Texas -- Cytoreductive nephrectomy improved overall survival (OS) by more than a year for patients with metastatic renal cell carcinoma (mRCC) with sarcomatoid or rhabdoid (S/R) ...

Credit: Getty Images With effective modern systemic therapies for metastatic RCC, how cytoreductive nephrectomy affects quality of life has become an increasingly relevant question, according to ...

Researchers writing in JAMA Network Open report that for patients with metastatic clear cell renal cell carcinoma, removing the kidney and its primary tumor is not associated with improved overall ...

A Canadian study recently assessed 709 patients with intermediate- and high-risk synchronous mRCC with or without sarcomatoid features. Most patients had clear cell histology and were treated with ...

Please provide your email address to receive an email when new articles are posted on . Thirty-five percent of patients who received targeted therapy for renal cell carcinoma underwent cytoreductive ...

Please provide your email address to receive an email when new articles are posted on . Pretreatment with sunitinib followed by deferred cytoreductive nephrectomy did not improve 28-week ...

The presentation of renal cancer in patients with flank pain, an abdominal or flank mass, and hematuria is now uncommon (<5% of cases). About 70% of patients are diagnosed following incidental ...

Surgical Management of Advanced Kidney Cancer: The Role of Cytoreductive Nephrectomy and Lymphadenectomy The following represents disclosure information provided by authors of this manuscript. All ...

Renal cell carcinoma presents with metastatic disease in approximately 30% of patients at the time of diagnosis. Cytoreductive nephrectomy (CN) of the primary tumor in the face of metastatic disease ...

Although retrospective data supported a similar survival benefit for cytoreductive nephrectomy in the targeted therapy era as it did for the initial immunotherapy era (1992 to 2006), level 1 evidence ...